Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-014198
Filing Date
2025-02-14
Accepted
2025-02-14 16:32:39
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9157
  Complete submission text file 0001104659-25-014198.txt   10890
Mailing Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840
Business Address 130 MAIN ST. 2ND FLOOR NEW CANAAN CT 06840 203-404-1172
Nantahala Capital Management, LLC (Filed by) CIK: 0001472322 (see all company filings)

EIN.: 201151760 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Subject) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92155 | Film No.: 25629776
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)